


#### FIRST IN HUMAN ISCHEMIC VT ABLATION SUCCESFULLY PERFORMED IN ICMR

# **Highlights**

- Amsterdam University Medical Centre (Amsterdam UMC) successfully performed the world's first ischemic ventricular tachycardia (VT) ablation guided entirely by real-time MRI using Imricor's suite of products
- First-in-human MRI-guided transseptal crossing performed using Imricor's NavTrac-MR® Transseptal Kit and Needle
- First left ventricular mapping and ablation performed with Imricor's Vision-MR<sup>®</sup>
  Ablation Catheter 2.0
- First substrate (scar)-guided ablation performed under real-time MRI guidance
- First ablation performed under real-time MRI guidance in a patient with an implantable cardioverter defibrillator (ICD)
- Upon completion, the patient was non-inducible for VT, signifying acute success for the procedure


**4 November 2025** – Melbourne, Australia (**3 November 2025** – Minneapolis, MN United States) – **Imricor Medical Systems, Inc.** (**Company** or **Imricor**) (**ASX: IMR**), together with Amsterdam University Medical Centre (Amsterdam UMC), is pleased to announce the successful completion of the first ischemic ventricular tachycardia (VT) ablation ever performed under real-time MRI guidance in an iCMR lab.

The Amsterdam UMC team, shown here, performed the VT ablation procedure following previous experiences performing atrial flutter and premature ventricular complex (PVC) ablation



Dr. Michiel Kemme (right foreground) performed the VT ablation.

Regarding the procedure, Dr. Kemme, stated: "This procedure is part of an international research programme. The MRI imaging shows us precisely where the myocardial infarction took place; therefore, we can send the catheter to the exact spot. This





Ischemic VT is one of the most challenging and life-threatening arrhythmias. Conventional VT ablations can routinely take more than 8 hours and deliver success rates as low as 40 percent. Until now, Imricor technology has been used for atrial flutter and PVC ablations. These earlier



procedures have been essential stepping stones towards fulfilling the 20-year vision of performing the most complex of ablations under the full power of real-time MRI guidance.

The procedure, successfully performed by the outstanding team at Amsterdam UMC, involved several world firsts. Crossing the septum, from the right side of the heart to the left had never been performed in a human under MRI guidance. This is a critical step in moving towards complex ablations for atrial fibrillation (AF) and VT, which together make up over 80% of ablations performed.

**Dr Kemme further noted:** "Thanks to the interventional MRI, we can see exactly in 3D where the sheath and ablation catheter are. This allowed us to move from the right atrium to the left atrium through the septum. It gives us much more information than the usual method."

In another world first, ablation lesions were delivered from within the ventricle under real-time MRI guidance. In addition, many VT patients live with an Implanted Cardioverter Defibrillator (ICD), implanted to protect the patient from sudden cardiac death. This procedure was the first to demonstrate the ability to safely and effectively treat high risk patients in the iCMR lab, even with an ICD onboard. This has been one of the remaining questions from the field, which has been answered via this procedure.

## **Impact**

This milestone marks a critical step forward for Imricor's VISABL-VT clinical trial, and a watershed moment for the field of MRI-guided electrophysiology. The achievement reflects the culmination of years of collaborative innovation, combining Imricor's advanced device portfolio with the world-class clinical expertise of the team at Amsterdam University Medical Centre. The successful procedure paves the way for broader clinical use of MRI-guided ablations, with additional sites in Europe expected to join the VISABL-VT trial over the coming months.



Prof Cornelis Allaart at the NorthStar® console while Dr Michiel Kemme performs the VT ablation.

The ability to perform complex ablations, like VT, under real-time MRI guidance has been the most requested advancement from the global EP community. With a growing pipeline of customers progressing towards performing atrial flutter ablations, Imricor expects the news of the world's first Ischemic VT ablation performed in an iCMR lab to drive significant growth in demand and shorten conversion timelines across its customer base.



**Imricor's Chair and CEO, Steve Wedan, commented:** "This is a defining moment for Imricor and for the field of electrophysiology. Performing the world's first ischemic VT ablation entirely inside the MRI validates our core vision, that real-time MR guidance can unlock safer, more effective, and more personalized treatments for patients with complex arrhythmias.

"The world-class team at the Amsterdam University Medical Centre has made a tremendous leap forward for the world, and I congratulate and thank them for this historic achievement. Together, we are paving the way for a future where MRI-guided procedures become the global standard of care.

"I also want to congratulate the extraordinary team at Imricor who accomplished something no one else has ever been able to do, by delivering all the devices, systems, partnerships, collaborations, regulatory processes, and clinical development that make this all possible.

"This milestone settles the science and opens the future. The ability to perform complex ablations entirely inside the MRI is no longer theoretical. It's real, and it's just the beginning of a worldwide transformation in how electrophysiology, and other interventions, are performed."

## **ENDS**

Authorised for release by Steve Wedan, Executive Chair, President, and CEO.

## **Media and Investor Relations Contacts:**

Simon Hinsley
Executive Director, NWR
simon@nwrcommunications.com.au
+61 401 909 653

Nick Corkill VP Corporate Strategy, Imricor nick.corkill@imricor.com +61 450 475 633

#### **About Imricor**

Imricor Medical Systems, Inc. (ASX:IMR) is striving to make interventional medical procedures better, safer, and more cost effective by making it possible for these procedures to be performed under real-time magnetic resonance imaging (MRI) guidance, rather than under x-ray fluoroscopy guidance, thus taking advantage of MRI's superior imaging capabilities.

#### **Imricor's Products**

Imricor is a pioneer and world leader in developing MRI-compatible products for cardiac catheter ablation procedures. The Company's products include capital equipment, such as the NorthStar® Mapping System and the Advantage-MR® EP Recorder/Stimulator. Single-use devices include a variety of ablation catheters, diagnostic catheters, steerable sheaths, and other tools used for cardiac ablations.

Imricor's products are approved in the European Union, the Kingdom of Saudi Arabia, and New Zealand. US FDA approval is in process, and further approvals in other geographies such as Australia are being planned.



#### **Foreign Ownership Restrictions**

Imricor's CHESS Depositary Interests (**CDIs**) are issued in reliance on the exemption from registration contained in Regulation S of the US Securities Act of 1933 (**Securities Act**) for offers which are made outside the US. Accordingly, the CDIs have not been, and will not be, registered under the Securities Act or the laws of any state or other jurisdiction in the US. As a result of relying on the Regulation S exemption, the CDIs are 'restricted securities' under Rule 144 of the Securities Act. This means that you are unable to sell the CDIs into the US or to a US person for the foreseeable future except in very limited circumstances after the expiration of a restricted period, unless the re-sale of the CDIs is registered under the Securities Act or an exemption is available. To enforce the above transfer restrictions, all CDIs issued bear a 'FOR US' designation on the Australian Securities Exchange (**ASX**). This designation restricts any CDIs from being sold on ASX to US persons. However, you are still able to freely transfer your CDIs on ASX to any person other than a US person. In addition, hedging transactions with regard to the CDIs may only be conducted in accordance with the Securities Act.

## **Forward-Looking Statements**

This announcement contains or may contain forward-looking statements that are based on the Company's management's beliefs, assumptions and expectations and on information currently available to management. All statements that address operating performance, events or developments that we expect or anticipate will occur in the future are forward-looking statements. These include, without limitation, EU commercial market acceptance and EU. sales of our product as well as our expectations with respect to our ability to develop and commercialise new products. Management believes that these forward-looking statements are reasonable when made. You should not place undue reliance on forward-looking statements because they speak only as of the date when made. Imricor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. Imricor may not actually achieve the plans, projections or expectations disclosed in forward-looking statements. Actual results, developments or events could differ materially from those disclosed in the forward-looking statements.